SLC5A2 and diabetes mellitus: In propensity‐matched cohorts, SGLT2 inhibitor use was associated with a lower risk of 1‐year mortality and heart failure readmission than DPP‐4 inhibitor use, even in patients with diabetes aged >75 years.78